AI Quick Summary

🔍 Meet the Residents Across Our SI Parks! 🔎🚀 @Simon Ittig of @T3 Pharmaceuticals was among the first who chose to establish his company @Switzerland Innovation Park Basel Area Main Campus. Two key factors influenced his decision: the physical closeness to his team and the dynamic exchange of ideas with neighboring innovators.🧬 At the core of T3 Pharma's innovation is an efficient protein delivery technology based on the use of live bacteria. Originally a spin-off of the @Biozentrum, University of Basel, the team has diversified the technology's applications in research and has specifically developed it as a novel therapeutic to treat solid tumors.🏆 During its launch seven years ago, it was supported by the startup accelerator and incubator @BaseLaunch. And then it went on to win many awards such as the @Swiss Economic Forum award 2021 or the @W.A. de Vigier Foundation’s award in 2019, T3 Pharmaceuticals also received funding from the Swiss Accelerator by @Innosuisse in 2023 to develop its bacterial cancer therapy platform.🌐 In November 2023, the German pharmaceutical company @Boehringer Ingelheim announced the acquisition of T3 Pharmaceuticals for an amount of up to 450 million CHF. Simon Ittig and his team will continue operations in the Basel region. We wish T3 Pharma and Boehringer Ingelheim much success in advancing the treatment of cancer and improving the lives of patients.🔗 Discover more about T3 Pharmaceuticals: https://www.t3pharma.com/🔗 For more information about the exciting developments at Switzerland Innovation Park Basel Area Main Campus https://sip-baselarea.com/news/four-new-builidings-main-campus/ #SwitzerlandInnovation #WhySwitzerland #SuccessStory #ImmunoOncology #cancertherapy #pharmaceuticals #medical

Post Metadata

• Author: Switzerland Innovation Digital
• Published Date: 7/25/2024 11:33:26 AM
• Modified Date: 9/24/2024 12:31:40 PM

Post Description

🔍 Meet the Residents Across Our SI Parks! 🔎

🚀 @Simon Ittig of @T3 Pharmaceuticals was among the first who chose to establish his company @Switzerland Innovation Park Basel Area Main Campus. Two key factors influenced his decision: the physical closeness to his team and the dynamic exchange of ideas with neighboring innovators.

🧬 At the core of T3 Pharma's innovation is an efficient protein delivery technology based on the use of live bacteria. Originally a spin-off of the @Biozentrum, University of Basel, the team has diversified the technology's applications in research and has specifically developed it as a novel therapeutic to treat solid tumors.

🏆 During its launch seven years ago, it was supported by the startup accelerator and incubator @BaseLaunch. And then it went on to win many awards such as the @Swiss Economic Forum award 2021 or the @W.A. de Vigier Foundation’s award in 2019, T3 Pharmaceuticals also received funding from the Swiss Accelerator by @Innosuisse in 2023 to develop its bacterial cancer therapy platform.

🌐 In November 2023, the German pharmaceutical company @Boehringer Ingelheim announced the acquisition of T3 Pharmaceuticals for an amount of up to 450 million CHF. Simon Ittig and his team will continue operations in the Basel region. We wish T3 Pharma and Boehringer Ingelheim much success in advancing the treatment of cancer and improving the lives of patients.

🔗 Discover more about T3 Pharmaceuticals: https://www.t3pharma.com/

🔗 For more information about the exciting developments at Switzerland Innovation Park Basel Area Main Campus https://sip-baselarea.com/news/four-new-builidings-main-campus/

#SwitzerlandInnovation #WhySwitzerland #SuccessStory #ImmunoOncology #cancertherapy #pharmaceuticals #medical